The Barclays stock research team released its recommendation report on December 12. Of the 24 stocks recommended by the investment bank in the US, Mexico and Canada, the five stocks with the greatest potential for growth were selected, as well as Barclays' forecast for their target prices and dividend returns over the next 12 months.

1. THC

Tenet Healthcare's investment in outpatients and auxiliary medical services attracted Barclays' attention. It is obvious that the company has not attracted the attention of the market. The company's earnings before tax, interest, depreciation and amortisation (EBITDA) is 6.5x, compared with 7.3x of its competitors. Barclays believes that due to the rapid growth of its services business, Tenet's enterprise value multiple will grow to 7.3 times. Its Conifer medical solution system is working with USPI (United Surgical Partners International Inc.) Jointly set up an outpatient surgery center.

Barclays has a target of $36 for Tenet's share price, up 137.2% from Friday's closing price of $15.18. Tenet health insurance shares have a downward target of $14, down just 7.8%. The company does not offer dividends.

2. Jazz Pharmaceutical (JAZZ)

As Barclays sees it, the development of Jazz's strong unlisted new drugs (pipeline) and the competition in its key types of drugs are less risky.

• Jazz Pharmaceutical's Xyrem (sodium hydroxybutyrate), an orphan drug, is currently the only drug approved by FDA for the treatment of sudden myasthenia gravis (cataplexy) and daytime narcolepsy (EDS:Excessive daytime sleepiness) associated with sudden narcolepsy (Narcolepsy). With 14 patents, the drug will benefit from the reduction of sodium in its new formulation, and the intellectual property protection period of the drug is expected to be extended.

• Barclays expects its leukemia drug Vyxeos to be approved by FDA.

• Its FDA-approved Defitelio is used in adults and children to treat hepatic vein occlusion (VOD) caused by blood stem cell transplants, which is the first drug approved in the United States to treat severe hepatic vein occlusion (VOD). Jazz will benefit from the sale of the drug in the US market.

All of these advantages prompted Barclays to forecast its target share price at $200, up 95.5 per cent from Friday's close of $102.30. Jazz Pharma's downside risk target price is $95, with a downward range of 7.1%. The shares of the company do not pay dividends.

3. Mobileye (MBLY)

Barclays believes that Mobileye's products are likely to be at the heart of the change in the automotive industry, with the company's ADAS (advanced driving assistance system) leading the industry and software increasingly becoming the core technology of self-driving cars. Mobileye's main business is to provide chips and software for the cameras of those driving systems. Barclays believes its products are easy to expand and customize on demand. The company's profits are like "a software company" with many partners. If the self-driving car industry starts to show explosive growth, the company will become a "pig in the tuyere".

The company is the most effective profit point for investors to follow the development of the self-driving car industry, and Barclays has set its target price at $60, up 68.6% from $35.58 at Friday's close. MBLY does not offer dividends. The downside risk of the company's share price is to be taken the lead by new competitors, for which Barclays has a target price of $10, a drop of 68.6%.

4. Goldcorp (GG)

Finally got to the point-gold mining stocks. Although Canada-based gold producer Goldcorp has been forced to lower its future expectations due to poor performance in Penasquito and Eleonore, Barclays believes its new management will push the company's valuation higher. The future of the company's business depends on the price of gold and the performance of the company's leading position in the industry. Barclays is optimistic.

For Goldcorp, Barclays set a target price of $19, 43.9% higher than Friday's closing price of $13.20. In addition, the company's stock carries a dividend yield of 1.8%. In terms of share price risk, Barclays fell 24.2% to $10.

5. FEMSA (FMX)

Given that President-elect Trump is very unfriendly to his southern neighbors, it is a surprise that FEMSA (US stock code: FMX), based in the northeastern Mexican city of Monterrey, appeared on Barclays' stock selection list. The business of this company is very easy to distinguish.

Barclays argues that this fragmented strategy makes FEMSA better able to withstand political risks than other Mexican companies. FEMSA's expansion in South America also deserves investors' attention.

Barclays estimated its target share price at $109, up 37.5% from Friday's close of $79.28. In addition, the dividend yield on the stock is 0.3%. A sharp drop in the Mexican peso in the future, coupled with a drop in retail and medical sales, will keep the company's minimum target price at $85, still up 7.2%.